CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 85 enrolled
Drug / intervention
cisplatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00792701
NCT00792701Phase 2Completed

Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)

SWOG Cancer Research Network·interventional·Posted Nov 18, 2008·Updated Mar 6, 2020

In Brief

A Phase 2 clinical trial evaluating cisplatin and gemcitabine hydrochloride for Lung Cancer. Completed, enrolled 85 participants across 147 sites.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy drugs after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. PURPOSE: This phase II trial is studying how well giving gemcitabine together with cisplatin works in treating patients with stage I non-small cell lung cancer that was removed by surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 18, 2008
Enrollment StartNov 1, 2008
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 17.6 years ago

Interventions

cisplatindrug

Given IV

gemcitabine hydrochloridedrug

Given IV